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Organic synthesis underpins the evolution of weak fragment hits into potent lead compounds. Deficiencies
within current screening collections often result in the requirement of significant synthetic investment to
enable multidirectional fragment growth, limiting the efficiency of the hit evolution process. Diversity-
oriented synthesis (DOS)-derived fragment libraries are constructed in an efficient and modular fashion
and thus are well-suited to address this challenge. To demonstrate the effective nature of such libraries
within fragment-based drug discovery, we herein describe the screening of a 40-member DOS library
against three functionally distinct biological targets using X-Ray crystallography. Firstly, we demonstrate
the importance for diversity in aiding hit identification with four fragment binders resulting from these
efforts. Moreover, we also exemplify the ability to readily access a library of analogues from cheap
commercially available materials, which ultimately enabled the exploration of a minimum of four
synthetic vectors from each molecule. In total, 10–14 analogues of each hit were rapidly accessed in
three to six synthetic steps. Thus, we showcase how DOS-derived fragment libraries enable efficient hit
derivatisation and can be utilised to remove the synthetic limitations encountered in early stage
fragment-based drug discovery.Introduction
In the twenty years since its conception, fragment-based drug
discovery (FBDD) has evolved into a mainstream approach to
develop bioactive compounds. Three drugs originating from
this technique have now been approved, whilst over 30 FBDD-
derived clinical candidates remain under evaluation high-
lighting the effectiveness of this strategy.1,2 The fundamental
challenge of developing potent molecules from the small,
weakly bound initial hits that are identied by this method,
however, should not be underestimated. Hits must beambridge, Lenseld Road, Cambridge,
ick, Coventry, UK
and Innovation Campus, Didcot OX11
versity of Oxford, Oxford, OX3 7DQ, UK
of Cambridge, Tennis Court Road,
ent of Medicine, University of Oxford,
of Chemistry 2020strategically optimised through fragment growing,3 linking4 or
merging,5 oen guided by structural information. In early
development, this can be achieved using commercial
compounds via an SAR-by catalogue approach,6,7 however, with
less trivial fragments and as the research evolves, this rapidly
becomes challenging. In this context, organic synthesis is a vital
component that can contribute to the viability of a given early-
stage drug discovery project.
Since the emergence of this strategy, physicochemical
constraints have been used to assemble collections of mole-
cules to screen based upon the properties of successful hitsgHit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK
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View Article Onlinefrom early campaigns, now termed the Rule of Three (Ro3).8
Indeed, several commercial libraries adhering to these criteria
are now readily available from many vendors. However, in
recent years, in addition to the Ro3 compliance, synthetic
accessibility and the ability to derivatise fragment molecules
have been noted as important but arguably less-well repre-
sented features.9,10 As a result, calls from leaders within the eld
have focused on the necessity for the development of novel
fragments featuring multidirectional exit vectors with synthetic
tractability, including demonstration of available growth
vectors.10 Thus, within the community there has been a sus-
tained effort to design novel fragment libraries featuring 3-
dimensional (3-D) elements11–15 (such as high fraction of sp3
carbons) and polar functionality,16 both of which enable facile
fragment elaboration. Moreover, despite the debate within the
literature on the relevance of 3-D fragments,17,18 recent examples
have validated the utility of enriching screening libraries with
these motifs.19–21
Diversity-oriented synthesis (DOS) is a strategy by which
libraries of structurally diverse compounds are constructed in
a rapid and synthetically efficient manner through the employ-
ment of divergent synthetic manipulations.22–25 Whilst tradition-
ally efforts in this eld were focussed on larger molecules, in
recent years the application of this methodology toward the
synthesis of novel 3-D fragments has emerged.26 Herein, we
demonstrate the relevance and utility of such libraries within
FBDD. Firstly, we validate the importance for diversity in
enabling identication of hits against several targets. In this case,
fragment binders for three distinct proteins from different
protein families were found from our recently published small
but shape diverse 40-member library (Fig. 1).27 This included
novel hits for challenging protein targets with no previously re-
ported small molecule binders. Secondly, we highlight how
molecules of this origin allow for analogues to be accessed in
a synthetically efficient manner, including complex quaternary
centre-containing compounds, in three to six steps from cheap
(<£3 per gram) and readily available startingmaterials. Finally, we
exemplify how the inherently modular chemistry can enableFig. 1 Demonstration of the utility of DOS libraries in X-ray based fragme
multiple 3-D vectors around initial hits in a facile manner. See ref. 27 for
Chem. Sci.fragment elaboration from a variety of vectors, with derivatives of
each hit exploring a minimum of four different positions.Results
With advances in foundational technologies such as third-
generation synchrotrons and high-throughput technolo-
gies,9,28–30 X-ray crystallography methods have since become one
of the most well-used techniques for hit nding within the eld
of FBDD.31 Thus, this method was selected as the primary
screening technique conducted through a collaboration with
the XChem platform.32 The DOS library was screened in
a racemic fashion to provide both enantiomers and was used in
a 500 mM§ format in d6-DMSO.Penicillin binding protein 3
The rst protein screened with our DOS library was penicillin
binding protein 3 (PBP3). The PBP family is responsible for the
synthesis and cross-linking of peptidoglycan, the major
component in the bacterial cell wall. The cell wall plays a pivotal
role in controlling the shape and integrity of the cell and inhi-
bition of the PBPs leads to cell lysis due to turgor pressure.33,34
The penicillin-binding domain contains a catalytic serine
residue, which is vital for its function and a useful target for
inhibition.35 Due to their essential role in cell division and
elongation, PBPs are attractive targets for antibiotics with many
b-lactam antibiotics developed for this purpose.36 However, the
efficacy and wide-spread use of b-lactams has driven the
alarming growth of bacterial resistance. Novel scaffolds capable
of inhibiting the PBP family are greatly needed to overcome
resistance mechanisms and restore activity against common
infections.37 Due to this imminent need for new antibiotic
leads, our DOS library was screened against P. aeruginosa PBP3
using the XChem platform.
This initial screen resulted in the serendipitous discovery of
1 as a covalent binder of PBP3 (PDB: 6Y6Z, Fig. 2), which
strikingly was the rst binder identied amongst approximately
1300 previous fragment soaks (see Table S1† for further details).
The core enol lactone scaffold was found to react with Ser294,nt screening and the ability to enable rapid analogue generation along
chemistry towards the library.
This journal is © The Royal Society of Chemistry 2020
Fig. 2 Initial hit compound 1 bound to PBP3, highlighted vectors suitable for diversification and the analogues synthesised to validate the initial
hit.
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View Article Onlinethe catalytic residue found within the conserved SXXK motif of
the b-lactam binding pocket. Upon incubation of the compound
with the crystals, resulting electron density maps suggested
a linear bound compound, which was hypothesised to result
from lactone ring-opening followed by enol tautomerization to
afford the linear ketone derivative. In addition to the covalent
bond, hydrogen bonding interactions were observed with
neighbouring residues Asn351, Ser349 and Thr487.
Considering these ndings, it was proposed that the iden-
tied hit could be rapidly diversied through four primary
vectors to comprehensively probe the PBP3 binding pocket. It
was envisaged that the quaternary centre could be substituted at
R1 with different alkyl (2, 3) and aryl groups (4), amide couplings
could be used to functionalise R2 (5–7), the terminal alkene
could be substituted at R3 (8, 9, 10) and the lactone ring size
could be altered (11). In this manner, exploring different ring
sizes would allow for core scaffold modication, which is oen
difficult to incorporate into early fragment development.
Importantly, substituents chosen for elaboration at R2 were
designed with key b-lactam inhibitors in mind.
The synthetic strategy used to access the proposed analogues
was based upon the original chemistry used to prepare the
library and utilised a common amino ester substrate in
a divergent process (Scheme 1). All four vectors were accessed in
ve synthetic steps. Firstly, to diversify the quaternary centre,
the R1 group in the commercially available ketoesters of type 12
could be varied. All examples shown here were purchased from
Sigma Aldrich for under £3 per gram. To begin, 12a–d wereScheme 1 Synthetic route to analogues of the initial PBP3 hit 1 in five s
This journal is © The Royal Society of Chemistry 2020condensed with p-anisidine to generate the p-methoxyphenyl
(PMP)-imine, which was subjected to a Barbier-type coupling
to install the alkyne handle, giving protected amines 13a–d. The
PMP-group was subsequently removed from 13a–d using
cerium ammonium nitrate (CAN), giving amines 15a–d. Alter-
natively, to access the tertiary carbon centre a simple substitu-
tion then deprotection of commercially available imine 14
allowed for easy access of amine 15e in high yields. In this case,
an alkyne featuring an extra methylene linker was employed to
enable downstream formation of the larger six-membered ring
derivative of 1. From these amine intermediates, a diverse range
of analogues were subsequently rapidly accessed using a simple
toolkit of reliable chemistries. HATU-mediated amide couplings
were exploited to connect a variety of motifs (R2) to the amine
using substrates 16a–d. Elaboration of this vector proved to be
highly efficient since the nal scaffold could be accessed in just
three steps from the common amine intermediate, and hence
many groups were explored with little synthetic effort.
Following amide formation, the ester groups within 17a–h were
readily hydrolysed using LiOH, yielding acids 18a–f. These nal
precursors could be cyclised using Cu(I)Br to form the unsatu-
rated lactone scaffolds 2–7, 10 and 11. Alternatively, a procedure
inspired by a reported one-pot Pd-catalysed cyclisation-coupling
reaction38,39 was used to vary the R3 alkene substitution,
enabling exploration of the nal vector and providing access to
8–10. This late-stage diversication provided extremely efficient
access to a variety of novel analogues from cheap, commercially
available aryl iodides.teps through key amine of type 15.
Chem. Sci.
Fig. 3 X-ray structure of 6 bound to PBP3 with conserved H-bonds
highlighted.
Chemical Science Edge Article
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View Article OnlineDue to the inherent design features of our fragment library
diversication of this fragment hit was simple, rapid and used
robust chemistry. The 10 elaborated analogues were then
screened using X-ray crystallography to validate the initial hit
and observe the effects of vector derivatisation on the PBP3
binding preference. All compounds except for 8–11 were iden-
tied as PBP3 binders using this method. This preliminary data
proved to be extremely useful in validating this hit with all
analogues covalently binding to Ser294 in a similar fashion to
that of 1, whilst the specicity for the 5-membered lactone and
terminal alkene could be inferred.
We found that fragment elaboration from the amine vector
(R2) was well-tolerated, including a variety of functionalities and
sizes (5–7). Interestingly, the phenol group of 6 was found to
project into a hydrophobic cle within the pocket, appearing to
make p–p interactions with proximal aromatic residues Tyr407
and Tyr409 (PDB: 6Y6U, Fig. 3, orange sticks), whilst main-
taining previously observed hydrogen bonding interactions.
These additional p–p interactions could prove extremely useful
for further medicinal chemistry efforts in the downstream
fragment evolution process.CFI25
To further demonstrate the utility of our library a second target
CFI25 (cleavage factor 25 kDa), an essential sub-unit of the pre-Fig. 4 Initial hit compound 19 bound to CFI25, highlighted vectors suitab
hit.
Chem. Sci.mRNA cleavage factor Im, was screened. This heterotetramic
complex comprises two units of CFI25 with two further units of
either CFI59 or CFI68.40,41 Numerous studies have shown CFI25 to
play a key role in determining the size of the 30 untranslated
region of mRNA, due to its involvement in the alternative pol-
yadenylation (APA).42 This important mechanism is involved in
gene regulation, ultimately contributing to the generation of
different mRNA isoforms.43 Crucially, several studies have
implicated CFI25 in oncology44 and neuropsychiatric disease45
settings, yet to date no small molecule modulators of this target
are known to enable the further elucidation of its function.
Thus, this served as an interesting target to explore with our
novel DOS fragment library.
Upon analysis of the resulting PanDDA event maps,46 two X-
ray hits were identied (PDBs: 5R4P and 5R4Q, Fig. 4 and S1†)
in a putative allosteric site away from the known mRNA
substrate channel.41,47 Importantly, as a result of the diverse
nature of the DOS library these hits related to distinctly
different chemotypes, highlighting the potential of this collec-
tion to deliver hits of varied molecular architecture.
To exemplify the ability of modular DOS methodologies to
enable rapid construction of varied analogues, hit 19 was
further investigated. The amenability of the DOS chemistry
toward multidirectional vector growth could be demonstrated
via derivatisation to almost every functionality within 19 (Fig. 4).
Specically, in line with the structural data, it was thought that
these investigations could include modication of the benzene
ring through substitution (20–28), variation in the bridging
heterocycle (29, 30), derivatisation of the pyrrolidinone hetero-
cycle via a-alkylation or ketone modication (31, 32) and nally
modication of the quaternary substituent R1 (33).
Importantly, in an analogous fashion to the explorations
around 1 all derivatives were directly formed from the same
quaternary amine intermediates of type 15 (Scheme 2). Firstly,
to access analogues bearing substituents (R2) on the benzene
ring amine 15a was acylated to give amide 34a. Next, Cu-
mediated click chemistry was performed on 34a using
a variety commercially available substituted azides 35a–j. In all
cases, the resultant triazole products 36a–j were obtained in
good yields. Next, precursors 36a–j were taken forward for cyc-
lisation to afford the desired pyrrolidinone analogues 20–28 viale for diversification and the analogues synthesised to validate the initial
This journal is © The Royal Society of Chemistry 2020
Scheme 2 A divergent scheme was harnessed to access analogues 20–33 starting from the key quaternary amine intermediate of type 15.
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View Article Onlinesubjection to Dieckmann condensation conditions followed by
thermal decarboxylation, which proceeded with good yields.
Next, using 34a in the same click reaction but exchanging the
azide component to a-chlorobenzaldoxime48 furnished the 1,4-
substituted isoxazole intermediate 37, which could again be
cyclised by employing the same conditions to afford 29. Alter-
natively, the 1,5-isoxazole variant could be obtained using the
same strategy but using a Ru-based catalyst,49 affording 38.
Once more, Dieckmann condensation followed by decarboxyl-
ation yielded 30. Finally, derivatives containing pyrrolidinone
modications were accessed through a late-stage modication
strategy from 19 through either ketone reduction to give 31, as
a diastereomeric mixture, or a-deprotonation followed methyl-
ation to give 32. In a similar fashion, modifying the R1 position
could be achieved using the phenyl quaternary amine 15d,
which was subjected to the above sequence to give 34b followed
by 39, and cyclised to give 33.
In this example, the highly modular and divergent DOS
strategy successfully enabled the rapid synthesis of 14 deriva-
tives of hit 19. These analogues were subsequently screened for
binding using a further round of X-ray crystallography. ThisFig. 5 (A) Hits that bound in allosteric site, 28¼ green sticks, 29¼ cyan
sticks, 32 ¼ yellow sticks and (B) 31 was found to bind in the substrate
channel.
This journal is © The Royal Society of Chemistry 2020data revealed of the nine substituted aromatic analogues (20–
28), only the p-uorine analogue 28 was tolerated within the
crystals (PDB: 5R4T, Fig. 5A, green sticks). Here, it was found
that the aromatic portion of the molecule bound in a similar
fashion to initial hit 19, with the amide carbonyl interacting
with Lys56 within the protein backbone. Similarly, the binding
of 29 (PDB: 5R4U, Fig. 5A, cyan sticks) revealed that the alter-
native isoxazole bridging heterocycle was also tolerated, again
in a similar binding pose to the original hit 19. Importantly,
selectivity for the 1,4-regioisomer could be inferred from these
results since no binding of the 1,5-isomer 30 was identied. In
an analogous fashion, 32 also exhibited this binding mode
(PDB: 5R4R, Fig. 5A, yellow sticks). Interestingly, in this case the
gem-dimethyl substituents and quaternary centre were oriented
toward different channels within the protein, suggesting these
positions could be utilised as two alternative 3-D growth vectors
from the molecule.
Conversely, soaking of 31 revealed this compound instead
bound within the distal mRNA substrate channel with a puta-
tive polar interaction between the amide carbonyl and the key
Arg63 residue known to mediate binding of the UUGUAU RNA
motif (PDB: 5R4S, Fig. 5B, binding protein residues in
orange).41,47 Additional interactions toward Arg150 and Gln157
further stabilised this binding. It is worth mentioning, as with
all bound derivatives, the electron density for the aromatic
region proved to be much more dened, whilst that of the
quaternary heterocycle was more ambiguous to assign. Thus,
whilst these interactions could be hypothesised, screening of
the single enantiomer or diastereomer variants of all four
binders would provide vital information about the true binding
preference and spatial orientation of the heterocycle. Building
on previous research in the eld of DOS fragments for hit
evolution,50 in this example we have demonstrated how this can
be achieved in a multidirectional fashion through leveraging
the inherent modularity, the quaternary motif and sp3 carbons
to provide insights into the most effective strategy for fragment
growth.Chem. Sci.
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View Article OnlineActivin A
The nal protein to be screened against our DOS-fragment
library was activin A. Activins are members of the trans-
forming growth factor b (TGF-b) superfamily of growth factors,
which play essential roles in homeostasis and development and
have been studied for many years.51 Research has shown acti-
vins mediate an intramolecular signalling cascade via binding
of the extracellular domains of transmembrane serine/
threonine kinases known as type I or type II receptors, ulti-
mately conducting the phosphorylation of Smad proteins
involved in target gene expression.52–54 Importantly, in this
context, binding of the type II receptors has been shown to be
crucial for type I receptor binding and therefore vital to initiate
the rst step of this signalling pathway. Several studies have
associated the role of activin A signalling with the regulation of
embryogenesis, stem cell differentiation and wound healing,
among other processes. Moreover, dysregulation of activin A
signalling or expression has been linked to human diseases
such as inammatory conditions, cancer and brodysplasia
ossicans progressiva.55–58 Nevertheless, despite the potential of
this target, to the best of our knowledge no small molecule
modulators of this protein exist to enable further investigations
into the associated biology. Thus, an XChem screen was con-
ducted leading to the identication of 40 as a binding partner
for activin A (PDB: 6Y6N, Fig. 6). This data suggested a key
hydrogen bonding interaction between the benzylic amide
carbonyl and the Trp28 residue within the site. This pocket is in
the predicted binding sites for the activin A type I receptor
ACVR1B/ALK4, proving an interesting avenue to pursue.
With the crystal structure and modular DOS route in mind,
several analogues were once more explored to showcase the
chemistry. It was proposed that the benzodiazepine core of the
molecule provided an opportunity for several points of deriva-
tisation, such as simple N-alkylation (R1) to form 41–44,
quaternary substituent modications at R2 (45, 46), including
enantiopure derivatives ((R)/(S)-40), alkyne chain modications
(R3, 47–49), removal of the quaternary substituents (50)
and nally amide modications (R4) e.g. 51 and 52. Once
more, this was proposed to commence via a divergent process
(Scheme 3A), utilising the same key amine intermediates 15b–d.Fig. 6 Initial hit compound 40 bound to activin A, highlighted vectors
validate initial hit.
Chem. Sci.Firstly, analogues bearing N-amide substituent variations at
the R1 position were pursued. Starting from 15b the acylated
intermediate 53a was accessed in good yield. To form 41 with R1
as hydrogen, 53a was subjected to nitro reduction using palla-
dium catalysis and nally hydride-mediated cyclisation of the
resultant amine toward the remaining ester functionality.
Alternatively, alkylation of 53a with a variety of alkyl halides and
catalytic TBAI afforded 54a–d. These acyclic precursors could
then undergo the same synthetic sequence of reduction and
cyclisation to give 42–44. Following this synthetic route, R2 was
explored using amines 15c and 15d, bearing variation of the
quaternary substituent. These were converted to 54e and 54f,
followed by 45 and 46 as previously described.
Next, to showcase the ability to readily access enantiopure
derivatives of both the key amine 15b and related analogues,
asymmetric routes to both (R)- and (S)-15b were pursued
(synthetic procedure, see ESI†). Following previously estab-
lished and reported chemistry from within the group,27 these
variants were also rapidly accessed from the same commercially
available ketoester starting material 12b in just four steps.
Following the previously described procedure, both enantio-
mers were converted to (R)-40 and (S)-40 via (R)- or (S)-53a and
-54a.
To modify the propyl chain (R3) of 40 and form 47–49, in this
instance 15b was acylated with 2-azidobenzoyl chloride to form
55. Surprisingly, upon subjection of this to the standard
methylation procedure, both 56a and 56b were formed as an
inseparable mixture of products. At this stage, the crude mate-
rial was telescoped into the zinc-mediated reduction step, fol-
lowed by cyclisation to generate separable material. Indeed,
both 47 and 48 were isolated. To further explore this vector in
a divergent fashion, the alkyne moiety within 48 was reduced
using palladium to give 49. Alternatively, to remove both
substituents from the quaternary position (Scheme 3B), sarco-
sine methyl ester hydrochloride could be utilised, which was
acylated to give 57 before reduction and cyclisation yielded 50.
Finally, two late-stage diversications of 40 were used to explore
R4. This included further alkylation of the amide to give 51 and
selective reduction of the unsubstituted amide to afford 52.
In total four vectors of the molecule were explored using the
14 analogues described. Once more, these compounds weresuitable for diversification and the analogues (41–52) synthesised to
This journal is © The Royal Society of Chemistry 2020
Scheme 3 Two synthetic strategies to access analogues of 40, (A) via key amine 15, (B) from sarcosine methyl ester hydrochloride.
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View Article Onlinerapidly accessed via short synthetic sequences from commercial
materials, highlighting the utility of the chemistry described. In
a subsequent round of crystallography, analogue 42 was found
to bind in the same pocket as the original hit, with the key H-
bond interaction toward the Trp28 residue conserved (PDB:
6Y6O, Fig. 7). This secondary binding data was useful to validate
the original hit binding and show the ethyl variant to be toler-
ated, suggesting the substituted amide position to be viable
growth vector for future synthetic efforts.Discussion
Herein, we have exemplied the ability of fragment-focused
DOS libraries to deliver diverse hits across numerous targets
from distinct protein families, despite originating from the
same amino ester building block. Screening of our DOS library
containing 40 compounds gave several structurally distinct and
tangible leads across all proteins considered. Importantly,
PBP3, CFI25, and activin A are indicators for completely unre-
lated therapeutic areas, and as such these hits have theFig. 7 Follow-up analogue 42 bound to activin A with conserved H-
bond to Trp28 highlighted.
This journal is © The Royal Society of Chemistry 2020potential to serve as novel starting points for the development of
inhibitors or chemical probes for a variety of biological
purposes. The hit identied against PBP3 binds through
a covalent mechanism, exemplifying the utility of our library
towards the discovery of novel covalent ligands, in addition to
reversible binders. Indeed, similar electrophilic fragments have
been demonstrated to have enhanced utility in probe develop-
ment due to their high duration of action and potency.59,60 We
also report, to the best of our knowledge, the rst small mole-
cule binders of CFI25 and activin A.61 Furthermore, subsequent
screens using the DOS library have also proven successful in
delivering novel hits against additional antibiotic targets, with
active discovery projects stemming from these results.
For these three proteins, four hits were identied, three of
which were then diversied to rapidly generate 10–14 analogues
in just three to six steps. All ketoester starting materials
described are commercially available, with costs under £3
per gram. Moreover, the reaction sequences used to access the
key amine intermediates of type 15 were readily and reproduc-
ibly prepared onmulti-gram scales. As a result, the timescales of
downstream analogue formation could be further reduced since
several analogues were accessed in a divergent manner from
this material. It is worth mentioning, as some examples have
highlighted, that removal of the quaternary substituent could
also be utilised as a strategy to decrease the number of steps
required to access analogues of this library. However, in all
projects described this feature was retained to exemplify the
ease of utilising this position as a growth vector. Indeed, deri-
vatisation of an sp3 quaternary carbon centre could prove highly
challenging for most fragment hits, yet due to the simple three-
step procedure previously developed, we have demonstrated
how analogues of library members with this feature could be
prepared with no additional route design.Chem. Sci.
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
4 
M
ay
 2
02
0.
 D
ow
nl
oa
de
d 
on
 5
/2
2/
20
20
 1
:4
6:
37
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineThe derivatives prepared explore at least four different frag-
ment exit vectors utilising simple chemical transformations,
offering signicant incentives for library implementation in
early FBDD programs. As discussed, one common hurdle within
FBDD follow-up work remains the investigation of suitable
points of hit modication to enable rapid and efficient explo-
ration of a given binding pocket. Here, we have shown how
novel libraries can be designed to alleviate this hurdle, allowing
for facile initial exploratory chemistry, oen where the mole-
cules are low on the value-synthesis trajectory.62
In all cases, the preliminary X-ray data was used to deduce
validation of each initial hit described, since at least one
analogue of all three were additionally found to bind within the
respective targets. In some cases, structural specicity could be
inferred based upon the lack of density observed for some
analogues. Thus, this initial scoping chemistry proved to be
a valuable technique to also probe the binding pockets and
derive potentially interesting vectors for further hit evolution
during future project objectives.
In this work, we have demonstrated the advantages of using
a DOS-derived library for FBDD lead validation and diversi-
cation. However, there are other factors which also limit hit
progression in FBDD, including the difficulty in attaining
additional biophysical characterisation required to generate
structure–activity relationship data. The hits and follow-up
compounds described in this work are currently under further
investigation, with the overall aim to conrm binding in
biophysical assays and ultimately produce potent lead
compounds for each protein.Conclusions
Herein, we have demonstrated that DOS-derived libraries are
useful tools for the generation of novel hits across a variety of
different biological targets. We identied four hits for PBP3,
CFI25, and activin A, all of which are functionally diverse
proteins with great relevance for developing novel therapeutics
as well as biological function elucidation. This further
strengthens the precedence for incorporation of 3-D, diverse
fragments within screening collections to augment existing
commercial compounds.
We also evidence how the strategic design of novel libraries
to incorporate modularity, whilst maintaining complexity, can
result in alleviating chemistry as a limiting factor in early
discovery projects. In this case, DOS methodology was exploi-
ted to facilitate rapid fragment elaboration, with up to 14
analogues of each hit readily accessed in short synthetic
sequences despite the formation of challenging quaternary
carbon centres. The additional advantage of these synthetic
sequences is their use of cheap commercial materials, which
reduces the requirement for lengthy and expensive initial
explorative chemistry. The library described is currently
available for screening via the XChem platform, where we hope
it will be utilised by the scientic community to provide novel
and more importantly tractable fragment hits for future
development.Chem. Sci.Author contributions
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